Miju LabsThere is no HIPAA in veterinary medicine. Animal medical records are the practice's property under state law with confidentiality norms attached, not a federal protected-health-information regime. No business associate agreement, no de-identification pipeline, no covered-entity relationship, no PHI insurance, no expert-determination statistician. The single largest cost and legal drag on every other niche in this dossier simply does not exist here.
That is the structural argument, and it is real. The commercial argument is weaker, and the honest version of this page has to say so.
The most interesting thing in the veterinary evidence is not about pets. VIPER — "An Expert-Curated Benchmark for Vision-Language Models in Veterinary Pathology" — comes from the Mahmood Lab, the group behind the leading human computational-pathology foundation models. It is 1,251 questions over 419 H&E-stained rat histology images across seven organ systems, all "curated and validated by board-certified veterinary pathologists," with 16 models benchmarked including two new veterinary-pathology models, seven human-pathology models and seven general frontier models (arXiv 2608.26382, GitHub).
Rat histology across organ systems is preclinical toxicologic pathology. That is a drug-safety artefact, built by a top human-pathology lab, using veterinary labour, outside HIPAA. It is the highest-value thread in this niche and it points at pharma preclinical safety rather than at the vet clinic.
What the artefact is
Five things, of which the last is the one that matters commercially:
- Radiograph, cytology and histology labels from board-certified veterinary specialists, with consensus structure.
- Long-form clinical QA with harm-weighted claim verification and citations.
- Vet-scribe note fidelity annotations against the encounter.
- Species- and breed-specific dosing and toxicology labels — the part of veterinary knowledge that transfers least and is therefore scarcest.
- Toxicologic-pathology labels on preclinical rat and dog histology. A pharma artefact wearing a veterinary coat: the labour is a veterinary pathologist, the buyer is drug safety, and the regulatory frame is GLP rather than HIPAA.
Does it need patient data
No, and the "no" is categorical rather than engineered.
Everywhere else in this dossier the PHI-free position is constructed — de-novo cases, synthetic charts, simulated conversations, each needing an annotation protocol designed to keep real patients out. Here there is no regime to stay outside of. Animal records raise a contractual confidentiality question with the practice that owns them, not a statutory one, and the answer is ordinary commercial licensing rather than de-identification.
That collapses data-acquisition cost. No expert-determination fee, no BAA negotiation with a hospital's legal department, no Safe Harbor scrub of narrative free text, no item-(R) argument about whether a rare presentation is itself identifying. See Build it without ever touching a patient record for what those cost in human medicine.
Residual constraints are ordinary: practice-owned records are the practice's, so de-novo authoring and public-domain material — teaching-hospital atlases, published case series — are the clean substrate. A vet writing labels is not practising, and malpractice exposure is far lower than human medicine, since animals are property and damages typically run to animal value plus treatment costs [UNVERIFIED on damages caps — jurisdiction-dependent]. See What the doctor on the other end is risking.
Is anyone buying
Budget scores 2, and this is where the long shot stops paying.
Mercor lists no veterinary role. Not a low band — no listing at all, across a healthcare page that itemises eighteen human roles down to prior-authorisation managers (Mercor). That is a confirmed absence, and it means there is no observed AI-data rate for a veterinarian anywhere in the record. Surge, Handshake and Scale show no veterinary offering either.
What exists instead:
- Vetology publishes 11 metrics per classifier — including a Radiologist Agreement Rate — across 89+ validated classifiers, built on 300,000 multi-image patient cases, "validated against board-certified veterinary radiologist consensus" (Vetology). A company already running radiologist-consensus labelling at scale: a customer or a competitor depending on whether it wants to keep running it.
- Zoetis is acquiring VitalRADS to expand its AI veterinary diagnostics platform (citybiz, 14 July 2026) — a $30B+ animal-health company and the deepest pocket in the sector.
- Mars Science & Diagnostics (Antech, Banfield, VCA) is using Azure AI for animal-health outcomes (Microsoft, 19 November 2024), and owns the largest veterinary diagnostics and practice network in the world. IDEXX is the other giant
[UNVERIFIED on AI data purchasing]. - Funded startups: Lupa $20M, Techcyte $15M, Vetic $40M led by Bessemer, plus a crowded vet-scribe tools market at $40–450/month (comparison).
Adoption is ahead of the tooling: a Digitail/AAHA survey found ~83% of respondents familiar with AI and nearly 30% already using it daily or weekly, with reliability and accuracy the top concern at 70.3% (AVMA).
The problem is size. Vet-AI rounds are $1.6M–$45M, not the $243M–$316M that Ambient scribing buyers raise. A $200k engagement is a large deal to a vet-AI startup and a rounding error to Abridge. The exceptions are the animal-health majors and pharma preclinical safety — which is the argument for the toxicologic-pathology angle rather than the pet-clinic angle. See Pharma, payers and providers.
Proof scores 4. No expert-data vendor is in this market, the academic benchmarks are public, and a consensus-panel product published with agreement statistics would be visibly the best commercial source almost immediately.
What the expert costs
Cost scores 4, dragged off 5 by imaging substrate rather than by labour.
BLS, Veterinarians, May 2025: median $130,100/yr = $62.55/hr; 91,100 jobs; +9% 2025–2035, "much faster than average" (BLS). That sits between nursing and pharmacy, and well below every physician specialty in this dossier.
Set against it: AVMA counts 133,475 US veterinarians as of 31 December 2025 (AVMA). The 42,000-person gap between licensed and employed is the available pool — vets not in full-time clinical practice are exactly the population that takes flexible expert work, and the same gap is invisible in Nursing only because the national RN licence count cannot be retrieved.
The cost that survives is the substrate. Radiographs, cytology and histology need images, and images need a licence from a practice network or a public atlas. Far cheaper than the human equivalent — Pathology notes only about 10% of US labs are digitised, a constraint that does not bind here — but not free the way a text artefact is.
There is no observed AI-data rate to price against, which means the first engagement sets the market. That is an opportunity and a risk in the same fact.
Getting to them
Reach scores 5, and the channel is unusually concentrated.
VIN — the Veterinary Information Network — is the dominant professional forum in the profession and the single most efficient recruiting channel in this niche. Nothing in human medicine has quite the same position; the closest analogue is r/medicine, which is far more diffuse.
Verification is straightforward. AAVSB operates VAULT, "the only organization in the U.S. or Canada to offer license transfer services," plus RACE for continuing education, VTNE for technicians and PAVE for international pathways (AAVSB), and every state veterinary board runs a public licence lookup. Board specialty verification runs through the colleges directly — ACVP for pathology, ACVR for radiology, ACVIM, ACVECC.
Other channels: AVMA and AAHA, r/veterinary, the VMX and WVC conferences, dvm360 and Vet Times. For the toxicologic-pathology thread specifically, the register is ACVP plus the CRO preclinical-safety functions — a much smaller and much better-paid population.
Professional-body attitude is neutral to positive: the AVMA raised ethical and legal questions and responded by forming a Task Force on Emerging Technologies and Innovation rather than demanding a pause. Compare National Nurses United in Nursing.
Where the benchmarks sit
| Benchmark | Origin | Construction |
|---|---|---|
| VIPER | Mahmood Lab | 1,251 questions, 419 H&E rat histology images, seven organ systems, board-certified vet pathologists; 16 models; public (arXiv) |
| VetScore | PrimVeterinary + Charles University | 1,200 segments, 4,986 claims from 67 queries across six LLMs; each claim annotated by three veterinary experts, at least one a practitioner with 3+ years; nine judge models (arXiv 2608.03675) |
| ANI.ML / Guelph | ANI.ML Health Inc. | 42 veterinary oncology records in triplicate, rubric co-developed with a board-certified clinician; Gemini 2.5 Pro as judge; Hachiko 4.61/5 vs 2.55 and 2.45 (arXiv 2510.01224) |
| VetLLM | Academic | Diagnosis prediction from veterinary notes |
| Cornell | Academic | "Data for Animal Health: Building Benchmarks for AI-Driven Veterinary Innovation" (Cornell) |
Three expert-curated benchmarks inside twelve months, one from a top-tier human-pathology lab. See The measurement landscape.
What would kill it
Room scores 4 and defense scores 4 — the room is real but the "zero competition" premise is not.
It is not uncontested. Academic labs got to the benchmarks first, and Vetology runs radiologist-consensus labelling at 300,000-case scale today. What is true is narrower and still valuable: no expert-data vendor sells into this market, and the benchmarks are published rather than commercialised.
Fragmentation is the technical killer. Canine, feline, equine, bovine, exotics — dosing, physiology and normal imaging appearance do not transfer. A benchmark claiming to cover "veterinary medicine" is really five benchmarks, and a product that pretends otherwise fails its first specialist review. That is the argument for narrowing to one species-and-modality pair, and a second argument for rat histology, where the species is fixed by the regulatory protocol.
Buyer size is the commercial killer. A vertical whose largest independent buyers raise $20–45M cannot support a specialist vendor alone. The animal-health majors and pharma preclinical safety can — which is why the veterinary thesis converts, on inspection, into a pharma-adjacent thesis with a veterinary labour pool.
Defense holds at 4 because board-certified veterinary pathologists and radiologists are genuinely scarce, ACVP and ACVR certification is a hard credential to fake, and the no-HIPAA position makes refreshing the corpus cheap in perpetuity.
Vetology clearly runs a radiologist-consensus operation at 300,000-case scale and discloses eleven performance metrics per classifier — but never what the labelling cost. Zoetis/VitalRADS and Mars/Antech budgets are entirely opaque. VetScore does not disclose annotator compensation. Mercor lists no veterinary role, so there is not even an intermediary rate card to triangulate from, as there is for the RN, the CPC and the PharmD elsewhere in this dossier. The whole veterinary sizing rests on inference from adjacent markets. Three phone calls — Vetology, an ACVP-certified tox pathologist at a CRO, and Zoetis diagnostics — would replace this paragraph with a number.
Where the record is thin
Whether the animal-health majors buy external labelled data at all is unestablished. Zoetis is acquiring a company; Mars is deploying a cloud platform; IDEXX has said nothing. Acquiring and deploying are not buying.
The toxicologic-pathology thread is inferred from one benchmark's construction, not from any disclosed CRO procurement. VIPER shows the artefact is technically live and that a serious lab thought it worth building. It does not show that a CRO buys expert labels, and no evidence either way was found.
Damages exposure for veterinary work is jurisdiction-dependent and uncharacterised, which matters for indemnity structure even though it is almost certainly small. Compare The health read and Characterised disagreement.